Table 1.
Demographic and clinical characteristics by treatment group before and after IPTW
| Fluconazole (N = 126) | Echinocandin (N = 181) | Standardized difference before IPTW | Standardized difference after IPTW | |
|---|---|---|---|---|
| Age (years), median (IQR)a | 60 (46, 69) | 60 (50, 75) | 11.4 | 2.4 |
| Male, n (%)a | 61 (48.4) | 115 (63.5) | −30.7 | 0.5 |
| Black race, n (%)a | 33 (26.2) | 39 (21.6) | −10.9 | −4.6 |
| Need for ICU resources the week prior to candidaemia onset, n (%)a | 53 (42) | 101 (56) | 27.7 | 5.1 |
| Need for vasopressors the day of candidaemia onset, n (%)a | 28 (22) | 67 (37) | 32.7 | 11.9 |
| Year of candidaemia onset, n (%)a | 24.6 | 2.7 | ||
| 2009 | 35 (55) | 29 (45) | — | — |
| 2010 | 34 (44) | 43 (56) | — | — |
| 2011 | 23 (31) | 51 (69) | — | — |
| 2012 | 17 (35) | 32 (65) | — | — |
| 2013 | 17 (40) | 26 (60) | — | — |
| Charlson comorbidity score, median (IQR) | 2 (1, 4) | 2 (1, 4) | NA | NA |
| LOS, median (IQR), days | 18 (8, 37) | 21 (10, 34) | NA | NA |
| LOS prior to candidaemia onset, median (IQR), days | 3 (0, 16) | 5 (0, 19) | NA | NA |
| Receipt of antifungal prophylaxis, n (%) | 20 (15.9) | 33 (18.2) | NA | NA |
| Healthcare-onset candidaemia, n (%) | 67 (53.2) | 98 (54.1) | NA | NA |
| Empirical antifungal, n (%) | 109 (86.5) | 162 (89.5) | NA | NA |
LOS, length of stay; NA, not applicable.
aVariable included in final propensity score model.